Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1085-1091

  Nakamura, Keiichiro ^a   Takamoto, Norio ^a   Hongo, Atsushi ^a   Kodama, Junichi ^a   Abrzua, Fernando ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptotic pathway; Caspase; Ovarian cancer; Secretory leukoprotease inhibitor

Indexed keywords

CASPASE 2; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSIENT TRANSFECTION; TUMOR VOLUME; BIOSYNTHESIS; CELL PROLIFERATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GLYCOSYLATION; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549117227     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1085     Document Type: Article

References (25)

1. Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, Brewer MT, Thompson RC and Crystal RG: Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 87: 2207-2215, 1991.
2. Franken C, Meijer CJ and Dijkman JH: Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 37: 493-498, 1989.
3. Jin FY, Nathan C, Radzioch D and Ding A: Secretory leukocyte protease inhibitor: a macrophase product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88: 417-426, 1997.
4. Boudier C, Cadene M and Bieth JG: Inhibition of neutrophil cathepsin G by oxidized mucus protease inhibitor. Effect of heparin. Biochemistry 38: 8451-8457, 1999.
5. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ and Dijkman JH: Antibacterial activity of anti-leukoprotease. Infect Immun 64: 4520-4524, 1996.
6. Shine N, Konopka K and Duzgunes N: The anti-HIV-1 activity associated with saliva. J Dent Res 76: 634-640, 1997.
7. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V and Ward PA: Inhibition of NF-kappaB activation and augmentation of Ikappa B beta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 154: 239-247, 1999.
8. Ward PA and Lentsch AB: Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 234-235: 225-228, 2002.
9. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY and Wahl SM: Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 6: 1147-1153, 2000.
10. Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, Niitsu Y and Nukiwa T: Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res 64: 4611-4620, 2004.
11. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A and Curiel DT: A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11: 1327-1335, 2005.
12. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
13. Linez LF: Deciphering the apoptotic pathway: all roads lead to death. Immunol Cell Biol 76: 1-19, 1998.
14. Griffith TS, Lynch DH and TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
15. Le Blanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003.
16. Wajant H, Gerspach J and Pfizenmaier K: Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16: 55-76, 2005.
17. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG and Ashkenazi A: Receptor selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280: 2205-2212, 2005.
18. King AE, Fleming DC, Critchley HO and Kelly RW: Regulation of natural antibiotic expression by inflammatory mediators and mimics of infection in human endometrial epithelial cells. Mol Hum Reprod 8: 341-349, 2002.
19. Stylianou E, Yndestad A, Sikkeland LI, Bjerkeli V, Damås JK, Haug T, Eiken HG, Aukrust P and Frøland SS: Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol 130: 279-285, 2002.
20. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Müller P, Koczan D, Thiesen HJ and Löhr M: Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23: 72-79, 2001.
21. Burvall K, Palmberg L and Larsson K: Expression of TNF alpha and its receptors R1 and R2 in human alveolar epithelial cells exposed to organic dust and the effects of 8-bromo-cAMP and protein kinase A modulation. Inflamm Res 54: 281-288, 2005.
22. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A and Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 96: 516-519, 2005.
23. Jin F, Nathan CF, Radzioch D and Ding A: Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophase-derived lipopolysaccharide inhibitor. Infect Immun 66: 2447-2452, 1998.
24. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV and Sallenave JM: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-κB-dependent inflammatory responses of human endothelial cells and macrophases to atherogenic stimuli. J Immunol 172: 4535-4544, 2004.
25. Odaka C, Mizuochi T, Yang J and Ding A: Murine macrophages producesecretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J Immunol 171: 1507-1514, 2003.